The winners and losers of Biden’s plans to expand coverage of weight-loss drugs US President Joe Biden wants to expand the ...
Novo Nordisk shifts its recruitment focus to China, expanding operations to meet rising demand for Ozempic and Wegovy in the ...
1d
Investors are assessing the likelihood Trump will deliver on his threat to impose fresh tariffs on China, Canada and Mexico.
Investors see Scott Bessent as a safe shepherd of the economy as the president-elect burnishes his "Tariff Man" reputation.
The Swiss aseptic fill-finish manufacturing specialist Baccinex has become the latest in a string of acquisitions by the ...
Novo Nordisk faces challenges in weight-loss sector, but acquisition and strong diabetes portfolio position it for future ...
Swiss medical technology company Ypsomed's contract with Novo Nordisk includes the supply of injection pens for the Danish ...
Thermo Fisher has launched a suite of expanded CRO and CDMO services under its own brand, Acceleratorâ„¢ Drug Development, intended to serve biotechs and pharmas.
A dose of four Wegovy injections will cost 1,400 yuan ($194), a fraction of the drug’s U.S. price, according to the Chinese ...
Once a leading player in the pharma sector, Wockhardt's journey has been tumultuous, yet it is now betting on Zaynich to turn ...
The pharmaceutical companies behind Ozempic, Wegovy and other weight-loss meds push to prevent compounding pharmacies from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback